Antonazzo, I.C.; Cortesi, P.A.; Miceli Sopo, G.; Mazzaglia, G.; Conte, P.; Mantovani, L.G.
The Value of Tucatinib in Metastatic HER2-Positive Breast Cancer Patients: An Italian Cost-Effectiveness Analysis. Cancers 2023, 15, 1175.
https://doi.org/10.3390/cancers15041175
AMA Style
Antonazzo IC, Cortesi PA, Miceli Sopo G, Mazzaglia G, Conte P, Mantovani LG.
The Value of Tucatinib in Metastatic HER2-Positive Breast Cancer Patients: An Italian Cost-Effectiveness Analysis. Cancers. 2023; 15(4):1175.
https://doi.org/10.3390/cancers15041175
Chicago/Turabian Style
Antonazzo, Ippazio Cosimo, Paolo Angelo Cortesi, Gerardo Miceli Sopo, Giampiero Mazzaglia, Pierfranco Conte, and Lorenzo Giovanni Mantovani.
2023. "The Value of Tucatinib in Metastatic HER2-Positive Breast Cancer Patients: An Italian Cost-Effectiveness Analysis" Cancers 15, no. 4: 1175.
https://doi.org/10.3390/cancers15041175
APA Style
Antonazzo, I. C., Cortesi, P. A., Miceli Sopo, G., Mazzaglia, G., Conte, P., & Mantovani, L. G.
(2023). The Value of Tucatinib in Metastatic HER2-Positive Breast Cancer Patients: An Italian Cost-Effectiveness Analysis. Cancers, 15(4), 1175.
https://doi.org/10.3390/cancers15041175
